Assyro AI

FDA Orange Book · active-ingredient family

Buprenorphine hydrochloride

Buprenorphine hydrochloride is approved as 4 brand and 15 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:PROBUPHINE · NDA 204442

4

Brand (NDA)

15

Generics (ANDA)

3

Listed patents

0

Exclusivity periods

Brand (NDA) products · film, implant, injectable, tablet

ProductApplicantApplicationTEApproved
PROBUPHINERLDREACX PHARMSNDA 204442May 26, 2016
BELBUCARLD×7BDSINDA 207932Oct 23, 2015
SUBUTEXRLD×2INDIVIORNDA 020732Oct 08, 2002
BUPRENEXRLDINDIVIORNDA 018401Approved Prior to Jan 1, 1982

Generic (ANDA) products (15)

ProductApplicantApplicationTEApproved
BUPRENORPHINE HYDROCHLORIDE×2ASCENT PHARMS INCANDA 219401ABDec 18, 2025
BUPRENORPHINE HYDROCHLORIDE×2SPECGX LLCANDA 218473ABDec 10, 2025
BUPRENORPHINE HYDROCHLORIDESOMERSET THERAPS LLCANDA 219302APJan 30, 2025
BUPRENORPHINE HYDROCHLORIDE×2RHODES PHARMSANDA 207276ABMar 27, 2017
BUPRENORPHINE HYDROCHLORIDE×2SUN PHARMANDA 201760ABJan 29, 2016
BUPRENORPHINE HYDROCHLORIDEPH HEALTHANDA 206586APJul 28, 2015
BUPRENORPHINE HYDROCHLORIDE×2RUBICON RESEARCHANDA 090279ABJun 10, 2015
BUPRENORPHINE HYDROCHLORIDE×2PHARMOBEDIENTANDA 201066Mar 06, 2015
BUPRENORPHINE HYDROCHLORIDE×2ACTAVIS ELIZABETHANDA 090819ABFeb 19, 2015
BUPRENORPHINE HYDROCHLORIDE×2ETHYPHARMANDA 090622ABSep 24, 2010
BUPRENORPHINE HYDROCHLORIDE×2BARRANDA 090360May 07, 2010
BUPRENORPHINE HYDROCHLORIDE×2HIKMAANDA 078633ABOct 08, 2009
BUPRENORPHINE HYDROCHLORIDEAM REGENTANDA 078331Mar 27, 2007
BUPRENORPHINE HYDROCHLORIDEHIKMAANDA 076931APMar 02, 2005
BUPRENORPHINE HYDROCHLORIDEHOSPIRAANDA 074137APJun 03, 1996

Listed patents (3)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9655843Jul 23, 2027in 1 yr 1 mo
ProductU-1556
8147866Jul 23, 2027in 1 yr 1 mo
ProductU-1769
9901539Dec 21, 2032in 6 yr 7 mo
U-1556

Buprenorphine hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.